AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Europe is putting its "ability to protect the health of its own people at risk", the CEO of FTSE 100 giant Astrazeneca has ...

The head of Britain’s largest drug company has demanded Europe ramp up spending on medicines amid fears over Donald Trump’s ...

Earnings preview of key companies reporting next week and what to look out for.

When Edward Sheldon asked the generative AI app for the best stocks to buy amid the market pullback, he was presented with ...

Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of ...

Platinum Asset Management’s flagship international fund initiated positions in several pharmaceutical companies in the ...

Image source: Getty Images. While elevator-down moves in the Nasdaq Composite ... that can be purchased with $300 while the ...

UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

Shares of several major pharmaceutical companies slumped Wednesday morning as President Donald Trump threatened tariffs on ...

Drugmaker AstraZeneca has teamed up with Indian digital ... The aim of the pilot is to scan and review more than 250,000 images generated at clinics in the Greater Manchester Cancer Alliance ...